Clinical Trial

Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension

Study acronym: ACTIBIO
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The ACTIOBIO study aims to evaluate the prognostic value of Activin-A and FSTL3 in a large cohort of patients with precapillary pulmonary hypertension, including pulmonary arterial hypertension (Group 1), pulmonary hypertension associated with lung diseases (Group 3), and chronic thromboembolic pulmonary hypertension (Group 4).
Trial Details
NCT Number NCT07253363
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Pulmonary Hypertension
Enrollment 550 participants
Start Date 2024-03-01
Primary Completion 2026-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-28